NCT06644118View on ClinicalTrials.gov

A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

PHASE1RecruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

October 23, 2024

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2028

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

OL-101 infusion

OL-101 infusion will be administered to patients via IV infusion at the assigned dose.

Trial Locations (3)

100071

NOT_YET_RECRUITING

Beijing Gobroad Boren Hospital, Beijing

710016

NOT_YET_RECRUITING

The Affiliated Hospital of Northwest University Xi'an No.3 Hospital, Xi’an

3100003

RECRUITING

The first affiliated hospital, College of Medicine, Zhejiang University, Hangzhou

Sponsors

Collaborators (1)

Overland Therapeutics
All Listed Sponsors
collaborator

Overland Therapeutics

UNKNOWN

lead

Zhejiang University

OTHER

NCT06644118 - A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) | Biotech Hunter | Biotech Hunter